home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Continuous inactivation of tumor suppressors helps maintain tumors

 
  February, 5 2007 20:19
your information resource in human molecular genetics
 
     
The latest research shows that continuous inactivation of the p53 tumor suppressor pathway is also required to maintain tumors in later stages of cancer. “This suggests that targeted therapies that act to reactivate tumor suppressors may be an effective new strategy to treat resistant cancers,” said Scott Lowe, Howard Hughes Medical Institute Investigator and Deputy Director of the Cold Spring Harbor Laboratory (CSHL) Cancer Center.

Using three distinct approaches in mouse models, Scott Lowe's group at CSHL, Tyler Jacks' lab at the Massachusetts Institute of Technology (MIT), and Gerald Evans' group at the University of California at San Francisco (UCSF) showed that reactivating or replacing p53 in mouse models of cancer causes tumors to regress.

Cancer is the result of numerous mutations in the genome that affect two major types of genes - tumor suppressors, and oncogenes. Mutations that cause tumor suppressor genes to become inactivated are thought to be responsible for the development and early stages of cancer, while persistent activation of a select few oncogenes, such as Myc and Ras, are known to be required for tumor maintenance in the later, malignant stages of cancer. While cancer therapies that target oncogenes have proven to be very effective in the treatment of cancers in recent years, these therapies often eventually fail as a result of new genetic mutations that cause resistance.

Surprisingly, tumor shrinkage in the Lowe study was seen to be the result of an immune response, most likely triggered by the release of cytokines such as interleukin from non-dividing cells in the tumor. A better understanding of this interaction between the body's natural defense mechanisms and tumor cells may lead to novel cancer treatments that specifically kill cancer cells, while sparing normal tissues.

CSHL is private, non-profit research and education institution dedicated to exploring molecular biology and genetics in order to advance the understanding and ability to diagnose and treat cancers, neurological diseases, and other causes of human suffering.


Message posted by: Rashmi Nemade

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.